These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 25424877)

  • 61. MicroRNA-520g promotes epithelial ovarian cancer progression and chemoresistance via DAPK2 repression.
    Zhang J; Liu L; Sun Y; Xiang J; Zhou D; Wang L; Xu H; Yang X; Du N; Zhang M; Yan Q; Xi X
    Oncotarget; 2016 May; 7(18):26516-34. PubMed ID: 27049921
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Mesothelium expression of vascular cell adhesion molecule-1 (VCAM-1) is associated with an unfavorable prognosis in epithelial ovarian cancer (EOC).
    Scalici JM; Arapovic S; Saks EJ; Atkins KA; Petroni G; Duska LR; Slack-Davis JK
    Cancer; 2017 May; 123(6):977-984. PubMed ID: 28263384
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The impact of pelvic retroperitoneal invasion and distant nodal metastases in epithelial ovarian cancer.
    Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Pérez-Milán F; Ortiz-Quintana L
    Surg Oncol; 2014 Mar; 23(1):40-4. PubMed ID: 24183480
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinical significance of the resistance proteins LRP, Pgp, MRP1, MRP3, and MRP5 in epithelial ovarian cancer.
    Sedláková I; Laco J; Caltová K; Červinka M; Tošner J; Řezáč A; Špaček J
    Int J Gynecol Cancer; 2015 Feb; 25(2):236-43. PubMed ID: 25594141
    [TBL] [Abstract][Full Text] [Related]  

  • 65. miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6.
    Xia B; Yang S; Liu T; Lou G
    Mol Cancer; 2015 Mar; 14():57. PubMed ID: 25889927
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines.
    Bai H; Li H; Li W; Gui T; Yang J; Cao D; Shen K
    Oncotarget; 2015 Sep; 6(28):25520-32. PubMed ID: 26267321
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Rac1 expression in epithelial ovarian cancer: effect on cell EMT and clinical outcome.
    Leng R; Liao G; Wang H; Kuang J; Tang L
    Med Oncol; 2015 Feb; 32(2):329. PubMed ID: 25585684
    [TBL] [Abstract][Full Text] [Related]  

  • 68. AEG -1 overexpression: a novel indicator for peritoneal dissemination and lymph node metastasis in epithelial ovarian cancers.
    Li C; Liu J; Lu R; Yu G; Wang X; Zhao Y; Song H; Lin P; Sun X; Yu X; Zhang Y; Ning X; Geng J
    Int J Gynecol Cancer; 2011 May; 21(4):602-8. PubMed ID: 21543927
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Does the primary route of spread have a prognostic significance in stage III non-serous epithelial ovarian cancer?
    Sahin H; Meydanli MM; Sari ME; Yalcin I; Çoban G; Ozkan NT; Cuylan ZF; Erdem B; Gungorduk K; Akbayir Ö; Dede M; Salman MC; Güngör T; Ayhan A
    J Ovarian Res; 2018 Mar; 11(1):21. PubMed ID: 29506569
    [TBL] [Abstract][Full Text] [Related]  

  • 70. miR-215 functions as a tumor suppressor in epithelial ovarian cancer through regulation of the X-chromosome-linked inhibitor of apoptosis.
    Ge G; Zhang W; Niu L; Yan Y; Ren Y; Zou Y
    Oncol Rep; 2016 Mar; 35(3):1816-22. PubMed ID: 26676658
    [TBL] [Abstract][Full Text] [Related]  

  • 71. α2,3-sialyltransferase type I regulates migration and peritoneal dissemination of ovarian cancer cells.
    Wen KC; Sung PL; Hsieh SL; Chou YT; Lee OK; Wu CW; Wang PH
    Oncotarget; 2017 Apr; 8(17):29013-29027. PubMed ID: 28423672
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Identification and prognostic value of differentially expressed proteins of patients with platinum resistance epithelial ovarian cancer in serum].
    Wu WJ; Wang Q; Zhang W; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2016 Jul; 51(7):515-23. PubMed ID: 27465871
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Overexpression of c-Abl predicts unfavorable outcome in epithelial ovarian cancer.
    Zhou S; Tang L; Wang H; Dai J; Zhang J; Shen L; Ng SW; Berkowitz RS
    Gynecol Oncol; 2013 Oct; 131(1):69-76. PubMed ID: 23820113
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Tyrosine kinase A receptor (trkA): a potential marker in epithelial ovarian cancer.
    Tapia V; Gabler F; Muñoz M; Yazigi R; Paredes A; Selman A; Vega M; Romero C
    Gynecol Oncol; 2011 Apr; 121(1):13-23. PubMed ID: 21236475
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Over-expression of CHAF1A in Epithelial Ovarian Cancer can promote cell proliferation and inhibit cell apoptosis.
    Xia D; Yang X; Liu W; Shen F; Pan J; Lin Y; Du N; Sun Y; Xi X
    Biochem Biophys Res Commun; 2017 Apr; 486(1):191-197. PubMed ID: 28286267
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Expression of phosphorylated Akt and hTERT is associated with prognosis of epithelial ovarian carcinoma.
    Lee YK; Chung HH; Kim JW; Song YS; Park NH
    Int J Clin Exp Pathol; 2015; 8(11):14971-6. PubMed ID: 26823830
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Prognostic and therapeutic implications of increased ATP citrate lyase expression in human epithelial ovarian cancer.
    Wang Y; Wang Y; Shen L; Pang Y; Qiao Z; Liu P
    Oncol Rep; 2012 Apr; 27(4):1156-62. PubMed ID: 22266777
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Annexin A2 plays a critical role in epithelial ovarian cancer.
    Deng Y; Chen C; Hua M; Xi Q; Liu R; Yang S; Liu J; Zhong J; Tang M; Lu S; Tang C; Wang Y
    Arch Gynecol Obstet; 2015 Jul; 292(1):175-82. PubMed ID: 25547062
    [TBL] [Abstract][Full Text] [Related]  

  • 79. MicroRNA-184 acts as a potential diagnostic and prognostic marker in epithelial ovarian cancer and regulates cell proliferation, apoptosis and inflammation.
    Qin CZ; Lou XY; Lv QL; Cheng L; Wu NY; Hu L; Zhou HH
    Pharmazie; 2015 Oct; 70(10):668-73. PubMed ID: 26601424
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Inhibition of gamma-secretase in Notch1 signaling pathway as a novel treatment for ovarian cancer.
    Feng Z; Xu W; Zhang C; Liu M; Wen H
    Oncotarget; 2017 Jan; 8(5):8215-8225. PubMed ID: 28030808
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.